Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarantus BioSciences has entered a collaboration agreement with Banyan Biomarkers, to investigate the efficacy of MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) in treating traumatic brain injury (TBI).
Subscribe to our email newsletter
MANF is a protein that corrects protein misfolding, which is the primary cause of apoptosis (cell death).
Under the collaboration, Amarantus will utilize its expertise in Central Nervous System disorders to expand the potential applications of MANF.
Amarantus president & CEO Gerald Commissiong said MANF would prove to be a potential treatment for these injuries and the research could become an important part of Amarantus’ overall strategy going forward.